




RealRate

MEDICINAL PRODUCTS 2023

BALCHEM CORP Rank 20 of 48





MEDICINAL PRODUCTS 2023

BALCHEM CORP Rank 20 of 48



The relative strengths and weaknesses of BALCHEM CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BALCHEM CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 51% points. The greatest weakness of BALCHEM CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 78%, being 83% points above the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	335,803
Assets, Non-Current	32,212
General and Administrative Expense	784,981
Goodwill	982,804
Liabilities, Current	202,826
Liabilities, Non-Current	40,620
Other Assets	2,338
Other Compr. Net Income	-2,161
Other Expenses	28,382
Other Liabilities	442,782
Other Net Income	-11,437
Other Revenues	942,358
Property, Plant and Equipment, Net	271,355
Research and Development	12,191

Output Variable	Value in 1000 USD
Liabilities	686,228
Assets	1,624,512
Expenses	825,554
Revenues	942,358
Stockholders Equity	938,284
Net Income	105,367
Comprehensive Net Income	104,286
Economic Capital Ratio	78%